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The central nervous system has a pattern of gene expression that is closely regulated with respect to functional and anatomical
regions. DNA methylation is a major regulator of transcriptional activity, and aberrations in the distribution of this epigenetic
mark may be involved in many neurological disorders, such as Alzheimer’s disease. Herein, we have analysed 12 distinct mouse
brain regions according to their CpG 5’-end gene methylation patterns and observed their unique epigenetic landscapes. The
DNA methylomes obtained from the cerebral cortex were used to identify aberrant DNA methylation changes that occurred in
two mouse models of Alzheimer’s disease. We were able to translate these findings to patients with Alzheimer’s disease,
identifying DNA methylation-associated silencing of three targets genes: thromboxane A2 receptor (TBXA2R), sorbin and SH3
domain containing 3 (SORBS3) and spectrin beta 4 (SPTBN4). These hypermethylation targets indicate that the cyclic AMP
response element-binding protein (CREB) activation pathway and the axon initial segment could contribute to the disease.
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Introduction
DNA methylation has a critical role in the regulation of gene
expression in tissues and organs (Cedar and Bergman, 2012) and
its deregulated patterns are increasingly associated with human
diseases (Feinberg, 2007; Heyn and Esteller, 2012), among which
feature a range of neurological disorders (Urdinguio et al., 2009;
Jakovcevski and Akbarian, 2012). In this latter context, epigenetic
marks, such as CpG methylation, may be essential because the
CNS is a highly specialized structure that requires fine-tuning for
gene expression. This is exemplified by the observations that it
expresses more alternatively spliced transcripts (Yeo et al., 2004)
and microRNAs (Cao et al., 2006) than any other tissue, and that
three out of four genes are active (Johnson et al., 2009). The role of
DNA methylation in the function of the CNS has been highlighted by
its involvement in memory formation (Miller and Sweatt, 2007; Feng
et al., 2010; Guo et al., 2011) and ageing-related cognitive decline
(Oliveira et al., 2012). Consequently, increasing interest is now
focused on the impact of aberrant DNA methylation patterns
in the origin and progression of Alzheimer’s disease. This, the
most common type of dementia, is characterized by insidious
degeneration of brain networks related to memory and cognition.
However, few genes are known to be deregulated by DNA
methylation in case-control studies of Alzheimer’s disease
(Siegmund et al., 2009; Bakulski et al., 2012; Rao et al., 2012).
The explanation for this paucity of results might be associated
with the existence of many distinctly functional subregions of
the brain that may have different DNA methylation patterns that
mask the analyses of the data, a matter that has only recently
been addressed, and even then, only for large brain regions (Ladd-
Accosta et al., 2007; Xin et al., 2010; Hernandez et al., 2011; Lee
et al., 2011; Davies et al., 2012). Most importantly, even if close to
80% of human genes are expressed in the brain, most of them are
expressed in a relatively small percentage of cells (i.e. 70.5% of
genes are transcribed in 520% of all cells) (Lein et al., 2007),
an important handicap to discover epigenetically altered genes in
specific cells because their DNA methylation patterns could be
diluted amongst the majority of cells with different epigenomic
patterns. We have addressed this challenging issue by carefully
microdissecting the 12 most relevant brain regions of the mouse
and hybridizing the corresponding samples to a DNA methylation
microarray. The observed DNA methylomes were used to identify
aberrant DNA methylation changes that occurred in two mouse
models of Alzheimer’s disease and to translate these findings to
patients with Alzheimer’s disease.
Materials and methods
Mice samples
Brain region profiles were derived from C57BL/6J mice obtained from
the Charles River laboratories. Twelve P60 samples (three female and
three male samples for the array hybridization and three female and
three male samples for the pyrosequencing validation) were used.
Mice were killed by cervical dislocation, and their brains were dissected
out within the first 2 min post-mortem and kept at 80C. Brain areas
were dissected from cryostat brain sections (20C) with the help of a
5 magnifying lens, following their stereotaxic coordinates (Paxinos
and Franklin, 2001), as previously described (Roux et al., 2003;
Panayotis et al., 2011a, b). For validations of epigenetically deregu-
lated genes in Alzheimer’s disease, frontal cortex samples from two
transgenic models were used, namely APP/PSEN1 (Borchelt et al.,
1997) and 3xTg-AD (Oddo et al., 2003) mice. Five 12-month-old
AbPP/PS1 and five wild-type littermates, and three 18-month-old
3TG and three 3TG control mice, were assayed for DNA methylation
using the mouse brain genome-wide promoter DNA methylation array.
Additionally, independent sets of 12-month-old AbPP/PS1 and five
wild-type littermates, and three 18-month-old 3TG and three 3TG
control mice were used for pyrosequencing validations and RNA
assays. Four APP/PS1 and four wild-type animals were deeply anaes-
thetized by intraperitoneal injection (0.2 ml/10 g body weight) with a
mixture of ketamine (100 mg/kg) and xylazine (20 mg/kg) before
intra-cardiac perfusion with 4% paraformaldehyde in PBS. Brains
were removed, post-fixed in the same fixative for 4 h and processed
for immunohistochemistry. Another group of four APP/PS1 and four
wild-type mice were sacrificed by decapitation and their brains quickly
removed, dissected on ice and immediately frozen and stored at
80C until processing for the immunoblot analysis. All animals
were maintained under standard animal house conditions in a 12-h
dark-light cycle with free access to food and water. The experimental
procedures complied with the European guidelines for the care and use
of laboratory animals (EU directive 2010/63/EU) and were approved
by the local ethics committee (UB-IDIBELL).
Human samples
Post-mortem tissues were obtained from the IDIBELL Biobank, which is
part of the eBrainNet Europe Bank (http://www.brainnet-europe.org/)
‘Network of Excellence’ funded by the European Commission in the
6th Framework Program ‘Life Science’ (LSHM-CT-2004-503039); the
CIEN Tissue Bank, CIEN Foundation, Instituto de Salud Carlos III; and
the University of California Irvine Alzheimer Disease Research Centre,
UCI Institute for Memory Impairments and Neurological Disorders. The
collection of all samples conformed to the relevant regulations, ethical
considerations and legislation as defined by the European Union and
Spain. Samples were dissected and characterized for Braak stage
before further examination. DNA and RNA from grey matter samples
of frontal cortex were extracted for pyrosequencing and RNA assay
validations. Only samples with RIN46.5 according to the RNA quality
test developed using the Agilent 2100 bioanalyzer were included in
the study. These filtered samples were DNA and RNA from grey
matter of frontal cortex (Brodmann area 9) of 20 controls [65%
female; age 71  3 years, post-mortem interval delay (PMI) 9  1 h,
mean  SEM] and 20 Alzheimer’s disease Braak stage V-VI (70%
female; age 82  2 years, PMI 8  1 h, mean  SEM) samples
matched for age and gender. Supplementary Table 1 describes in
detail the available clinicopathological information for all cases and
controls (Braak staging, PMI, age and gender). The PMIs were similar
for both groups.
Bisulphite conversion of DNA
The Repli-g whole genome-amplification kit (Qiagen) was used to
generate non-methylated DNA following the manufacturer’s protocol.
For methylated DNA, part of the resulting DNA was in vitro methy-
lated using SssI enzyme (New England Biolabs). The EZ DNA methy-
lation kit (Zymo Research) was used for bisulphite conversion of all
DNA samples used, according to Bibikova et al. (2009).
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Mouse brain genome-wide promoter
DNA methylation array
The mouse brain genome-wide promoter DNA methylation array is a
custom designed Illumina’s VeraCode GoldenGate DNA methylation
assay that was specifically enriched in genes related with sensory
perception, cognition, neuroplasticity, brain physiology and mental
diseases in order to provide a useful tool for subsequent neurological
studies. From the starting list of 762 genes we downloaded the tran-
scription start coordinates from http://genome.ucsc.edu using 2007
July mm9 assembly and UCSC Genes track. From genes with more
than one transcription starting site we selected the first at the 5’ end
of the gene. We took 750 bp upstream (5’) and 250 bp downstream
(3’) relative to the marked transcription site to design the specific
probe for the array, which was subsequently filtered for single
mapping on its specific chromosome position. The 384 genes with
the highest scores were included in the final design of the array
(Supplementary Table 2). Among the 384 amplicons, the average of
interrogated CpGs was 2.7 (Supplementary Table 2).
Data analysis
All data were analysed using the open-source statistical programming
language R (version 2.13.1). Quantile normalization of the array was
carried out using the lumi package and posterior analysis was done
with the genefilter package (Bioconductor). For general analysis, all
probes with detection values of P5 0.01 in 415% of the samples
(25 probes) and probes located on chromosome X (17 probes) were
excluded. Poor-quality samples (410% failed probes) were also
excluded. For unsupervised clustering analysis, probes with a general
standard deviation 50.05 were excluded as non-informative.
Subsequently, heatmaps were analysed using the gplots package.
Spectral map analysis was carried out using the mpm package
(Wouters et al., 2003). Statistical analysis was performed using the
lumi package (Mann-Whitney and Kruskal-Wallis tests for two- and
multiple-group comparisons, respectively, adjusting P-values with the
FDR algorithm).
Pyrosequencing
The set of primers for PCR amplification and sequencing
(Supplementary Table 3) were designed using the PyroMark assay
design program, version 2.0.01.15 (Qiagen); amplification primers hy-
bridize with CpG-free sites to ensure a methylation-independent reac-
tion and one primer (opposite the sequencing primer) is biotinylated to
convert the PCR product to single-stranded DNA templates. We used
1 ml of bisulphite-treated DNA for each PCR. In order to prepare
single-stranded PCR products, we used the Vacuum Prep Tool
(Qiagen), following the manufacturer’s instructions. Pyrosequencing
reactions and methylation quantification were performed in a
PyroMark Q24 System version 2.0.6 (Qiagen). All pyrosequencing
assays were run in triplicate. These technical replicates yielded stand-
ard errors of means 51%.
Real-time polymerase chain reaction
Total RNA purification and DNase treatment were performed using
TRIzol (Invitrogen) and the Turbo DNA-Free kit (Ambion). RNA was
reverse-transcribed using the Thermoscript RT-PCR system (Invitrogen)
and each PCR was carried out in triplicate using SYBR Green PCR
MasterMaster Mix (Applied Biosystems). Thermocycling conditions
were 10 min at 95C, then 50 cycles of 15 s at 95C and 1 min at
60C. Fluorescent signals were acquired by the ABI Prism 7900HT
Sequence Detection System (Applied Biosystems), and positive stand-
ard deviations were normalized using three housekeeping genes
(GUSB, RPL38 and TBP). The primers for real-time PCR are listed
in Supplementary Table 4. PCR efficiencies were calculated using
standard dilutions and the LinReg software (Ruijter et al., 2009).
Immunofluorescence and confocal
microscopy
Tissue samples were embedded in paraffin and 4 -mm coronal sections
were cut with a microtome. De-waxed sections were stained with a
saturated solution of Sudan Black B (Merck) for 30 min to block the
autofluorescence of lipofuscin granules present in cell bodies, then
rinsed in 70% ethanol and washed in distilled water. The sections
were treated with citrate buffer to enhance antigenicity, and then
incubated at 4C overnight with primary antibodies against Tbxa2r
(1:200, rabbit; Acris), F2rl2 (1:50, rabbit; Santa Cruz), Sptbn4
(1:100, rabbit; Sigma-Aldrich). After washing, the sections were incu-
bated with Alexa488 (1:400, Molecular Probes) fluorescence second-
ary antibody against the corresponding host species. After
counterstaining of nuclei with DRAQ5TM (1:2000, Biostatus), the sec-
tions were mounted in Immuno-Fluore Mounting medium (ICN
Biomedicals), sealed, and dried overnight. Sections were examined
with a Leica TCS-SL confocal microscope. The protein levels were
evaluated by densitometric quantification in reference to the GFAP
immunostained area in five representative pictures taken from the
neocortex of each animal using Adobe Photoshop CS4.
Immunoblot analysis
Frozen cortical areas were dounce-homogenized in lysis buffer (50 mM
Tris/HCl buffer, pH 7.4 containing 2 mM EDTA, 0.2% Nonidet P-40,
1 mM PMSF, protease and phosphatase inhibitor cocktails, Roche
Molecular Systems), incubated for 20 min with agitation at 4C and
centrifuged for 30 min at 16 000 g. The supernatant was recovered and
stored at 80C. Protein content was determined by the BCA method
(Thermo Scientific). Equal amounts of protein (20 mg per lane) were
separated by SDS-PAGE (10%) and transferred onto nitrocellulose
membranes (Amersham, GE Healthcare). Non-specific bindings were
blocked by incubation in 5% non-fat milk in Tris-buffered saline
(100 mM NaCl, 10 mM Tris, pH 7.4) containing 0.2% Tween (TTBS)
for 1 h at room temperature. Afterwards, membranes were incubated
overnight at 4C with the polyclonal mouse anti-SORBS3 (1:1000,
Abnova) in TTBS with 3% bovine serum albumin. Protein loading
was monitored using a mouse monoclonal antibody against b-actin
(1:30 000, Sigma-Aldrich). Membranes were then incubated for 1 h
in the appropriate horseradish peroxidase-conjugated secondary
antibodies (1:2000, Dako) and immunocomplexes were revealed
by an enhanced chemiluminescence reagent (ECL AdvanceTM,
Amersham Biosciences). Densitometric quantification was carried out
with TotalLab v2.01 software (Pharmacia). Protein bands were nor-
malized to b-actin levels and expressed as a percentage of the control
group level.
Results
We first carefully microdissected the 12 most relevant brain
regions of the mouse (cerebellar granular and Purkinje layers,
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frontal cortex, hippocampal regions CA1, CA3 and dentate gyrus,
basolateral amygdala, caudatus putamen, substantia nigra, hypo-
thalamus, globus pallidus and thalamus) and hybridized the cor-
responding DNAs obtained to a custom microarray containing the
5’-end regulatory regions of 384 mouse genes (Supplementary
Table 2). The list was specifically enriched in genes related to
sensory perception, cognition, neuroplasticity, brain physiology
and mental diseases. The CpG probes used were mapped to loca-
tions between 750 bp and + 250 bp of the corresponding tran-
scription start sites. Among the 384 amplicons, the average of
interrogated CpGs was 2.7. To test the reliability of the array
we used three different technical replicates randomly distributed
on the array. After quantile normalization, we obtained excel-
lent coefficients of correlation (r2 = 0.98, 0.99 and 0.99,
Supplementary Fig. 1) confirming the high reliability of the
method. Two important control samples were also included:
DNA fully methylated in vitro using the SssI enzyme (New
England Biolabs), as a positive methylated control for all CpG
sites, and a whole genome PCR amplified DNA obtained using
the Repli-g whole genome-amplification kit that does not retain
methylated CpGs (Qiagen), as a negative methylated control for
all CpG sites. The VeraCode assay recognizes the SssI-treated DNA
as highly methylated and the whole genome amplified DNA as
fully unmethylated (Supplementary Fig. 2A). We also interrogated
the linear capacity of the array, mixing different proportions of
methylated and unmethylated DNA generating a set of five dif-
ferent ratios (1:0, 2:1, 1:1, 1:2 and 0:1). The use of the above
described whole-genome amplified DNA as a negative control and
in vitro methylated DNA as positive control DNA obtained a high
Pearson’s coefficient of correlation (r2 = 0.97, Supplementary Fig.
2B). We further validated the VeraCode assay as a tool to measure
DNA methylation by the existence of inactivation of one X-
chromosome in females by DNA methylation, when compared
with the unmethylated X-chromosome in males. Herein, we
observed that those CpG sites located in the X-chromosome in
the VeraCode assay were able to discriminate between female
and male samples in brain regions (Supplementary Fig. 2C).
To further validate the array data (obtained using three female
and three male samples), we took advantage of the spectral map
analysis (Supplementary Fig. 3A) and performed pyrosequencing
of the most discordant regions for each of the genes identified
using an additional set of biological samples (a distinct group of
three female and three male samples). Herein, we obtained similar
ratios between both techniques and high overall correlation
(r2 = 0.721, Supplementary Fig. 3B and C). In addition, we
interrogated the biological relevance of such DNA methylation
correlating these data with the RNA expression profiles available
in Allen Brain Atlas database (Supplementary Fig. 4). In this
regard, we obtained an excellent correlation between both sets
of values (Fisher’s exact test P50.001) underlying its biological
significance. Using this approach, we identified 72 genes
(Supplementary Table 5) that were significantly differentially
methylated (FDR50.05) across the described 12 brain regions
of C57BL/6J mice, enabling them to be distinguished by the
hierarchical clustering approach (Fig. 1). The observed differences
were not associated with cellular heterogeneity at the level of glia
versus neuron lineage. When these two cell types were isolated in
the mouse brain using A2B5 and PSA-N-CAM antibodies, respect-
ively, followed by magnetic separation (Seidenfaden et al., 2006;
Strathmann et al., 2007) no significant differences in DNA methy-
lation were observed for seven studied genes (Spearman’s
correlation test, rho = 0.60, P = 0.166; Supplementary Fig. 3D).
Interestingly, the cluster analysis identified three main DNA
methylation branches corresponding to cerebellum (granular cell
layer and Purkinje cells), cerebral cortex (CX, CA1, CA3 and den-
tate gyrus) and diencephalon-basal ganglia (basolateral amygdala,
caudate-putamen, substantia nigra, hypothalamus, globus pallidus
and TH). These largely correspond with the major divisions of the
brain into hindbrain, forebrain and midbrain (Fig. 1). Thus, con-
sistent with the previously reported RNA expression profiles
(Johnson et al., 2009; Lein et al., 2007), our results suggest that
major brain divisions are not only structural bisections but also
have distinct functional significance. These DNA methylation
patterns also reflect the cell type composition of these regions:
diencephalon-basal ganglia, which are mainly enriched in
GABAergic neurons, and cerebral cortex, which is enriched in
glutamate neurons, cluster according to their cell characteristics
(Fig. 1). DNA methylation microarray data for 384 genes in the
12 studied mouse brain regions are available to download from
NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo): GSE47038.
The DNA methylation clustering analyses that recognize cerebral
cortex as a distinct branch are relevant to our understanding of
Alzheimer’s disease because this is the region most strongly af-
fected in the disorder. Thus, we made a detailed comparison of
the DNA methylation patterns in cerebral cortex and the rest of
the brain, the latter being regions that are not targeted in
Alzheimer’s disease. We identified 52 genes that were differen-
tially methylated between cerebral cortex and the rest of the brain
(Supplementary Table 6) (FDR5 0.05) and further investigated
the seven genes with the greatest differential methylation
(Fig. 2A). For six of these seven (86%) genes, we were able to
link the presence of high levels of DNA methylation at their 5’-end
regions with downregulation of the corresponding transcripts mea-
sured by quantitative real time-PCR (Fig. 2B), highlighting the
functional relevance of the observed epigenetic differences. To
determine if these genes underwent DNA methylation changes
in the disorder, we hybridized the frontal cortex samples from
two well-established models of Alzheimer’s disease in mice,
APP/PSEN1 and 3xTg-AD (Borchelt et al., 1997; Oddo et al.,
2003) to the DNA methylation microarray. Strikingly, we observed
that thromboxane A2 receptor (Tbxa2r), coagulation factor II
(thrombin) receptor-like 2 (F2rl2), sorbin and SH3 domain contain-
ing 3 (Sorbs3) and spectrin beta 4 (Spnb4) were hypermethylated
in the frontal cortex of APP/PSEN1 mice observing a similar trend
in 3xTg-AD mice (Fig. 2C). DNA methylation microarray data for
the 384 genes in the frontal cortex samples from control animals
and the two transgenic models APP/PSEN1 and 3xTg-AD are
available to download from NCBI Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo): GSE47036.
To achieve biological replication of the data obtained with the
first group of samples, we confirmed the hypermethylation of the
four genes identified above using an additional set of samples
from the frontal cortex of APP/PSEN1 and 3xTg-AD mice using
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Figure 1 Unsupervised heatmap clustering of a genome-wide promoter DNA methylation microarray across 12 brain regions in the
C57BL/6 mouse. A schematic representation of studied regions was performed on plates adapted from the mouse brain in a stereotaxic
coordinates atlas. The circles and areas mark sites from which brain tissue was dissected. The frontal cortex (distance from the bregma,
+ 2.68), caudate-putamen ( + 0.98), basolateral amygdala (0.90 to 0.95), hypothalamus (0.82), globus pallidus (1.20), thalamus
(1.34), hippocampus (1.94, hippocampal field CA3, CA1 and dentate gyrus, DG), midbrain area (substantia nigra + ventral tegmental
area, 3.08), and cerebellum (5.80, granular cell layer, GCL; Purkinje cells, PC) were microdissected. Red and green colours indicate
high and low levels of DNA methylation, respectively. Scale bars = 1 mm.
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a different DNA methylation technique, pyrosequencing (Fig. 2D).
The presented pyrosequencing values correspond to the average
level of CpG methylation across each amplicon and Supplementary
Fig. 5 shows methylation values for each CpG within the studied
amplicons. In these cases, we also linked the presence of the
hypermethylation events in the cortex from the Alzheimer’s
mouse models to the downregulation of the corresponding tran-
scripts (Fig. 2E) and proteins in the western blot of F2rl2, Sorbs3
and Spnb4 genes (Fig. 2F and Supplementary Fig. 6) and immuno-
fluorescence of Tbxa2r (Fig. 2F and G).
These encouraging results prompted us to investigate human
biological samples to address whether the observed epigenetic
changes occurred in patients with Alzheimer’s disease. We used
pyrosequencing to analyse the DNA methylation status of the four
validated genes (from which gain of 5‘-end methylation was asso-
ciated with diminished expression in the Alzheimer’s disease
mouse models) in a collection of 20 frontal cortex samples from
Alzheimer’s disease Braak stage V-VI cases, comparing them with
20 aged-matched control samples. As in the mouse models,
TBXA2R, SORBS3 and SPTBN4 were hypermethylated in the
human Alzheimer’s frontal cortex samples (Fig. 3A). The pyrose-
quencing values presented correspond with the average level of
CpG methylation across each amplicon and Supplementary Fig. 7
shows methylation values for each CpG within the studied ampli-
cons. We found an association between the gain in hypermethyla-
tion of TBXA2R, SORBS3 and SPTBN4 in the frontal cortex of the
patients with Alzheimer’s disease with a reduction of the corres-
ponding RNA transcripts (Fig. 3B) and proteins (Fig. 3C), reinfor-
cing the biological role of the identified epigenetic events. Finally,
we found a similar trend for F2RL2 DNA methylation and RNA
expression although the great variability of expression among
samples precluded a definitive conclusion for this gene.
It is worth mentioning that the 5’-ends of the human counter-
parts (F2RL2, SORBS3, SPTBN4 and TBXA2R) of the mouse genes
(F2rl2, Sorbs3, Spnb4 and Tbxa2r) validated as targets of epigen-
etic disruption in Alzheimer’s disease show structural and func-
tional homologies (Supplementary Fig. 8). In addition to the
chromosomic location of the corresponding homologous regions
between humans and mice, the 5’-ends of these four genes share,
in both species, a high number of identical transcription factor
binding sites (Supplementary Fig. 8A). Interestingly, this observa-
tion is particularly true for the nucleotide regions that contain the
CpG dinucleotides assessed by the DNA methylation microarray
and pyrosequencing (Supplementary Fig. 8B). Most importantly,
four of the transcription factor binding sites common in both spe-
cies, and located precisely within the CpGs with differential DNA
Figure 2 Epigenetic deregulation of target genes in Alzheimer’s disease brain regions in mice. Differential DNA methylation (A) and RNA
expression (B) for the top seven candidate genes that discriminate cerebral cortex from the rest of the brain (control C57BL/6 mouse).
Differential 5’-end DNA methylation patterns for Tbxa2r, F2rl2, Sorbs3 and Spnb4 according to DNA methylation microarray values (C)
and pyrosequencing (D) in the frontal cortex of APP-PSEN1 and 3xTg-AD Alzheimer’s disease mouse models in relation to their cor-
responding controls. Pyrosequencing values presented correspond to the average CpG methylation across each amplicon. The gain of
promoter hypermethylation for Tbxa2r, F2rl2, Sorbs3 and Spnb4 in the frontal cortex of APP-PSEN1 and 3xTg-AD Alzheimer’s disease
mouse models is associated with the downregulation of the corresponding RNA transcripts (E) and proteins, measured by western blot (F)
and immunofluorescence (G). *P5 0.05 in the Student’s t-test.
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methylation between cases and controls, show methylation-sensi-
tive binding affinity. These sites were TFAP2A (Kulak et al., 2012),
TBP (Bane et al., 2002), GATA-2 (Rui et al., 2013) and GATA-3
(Hutchins et al., 2002) (Supplementary Fig. 8C). In this regard, for
promoters without a CpG island, the methylation of particular
CpG sites surrounding the transcription start sites can also be
linked with transcriptional downregulation (Han et al., 2011;
Kelly et al., 2012; Øster et al., 2013). These findings warrant
further research in this area.
Discussion
As mentioned previously, 80% of total genes are expressed in
the brain and most are expressed in a relatively small percentage
of cells (Lein et al., 2007). It is an important handicap to elucidate
epigenetically deregulated genes in CNS because the characteristic
patterns that regulate the expression of concrete genes in specific
cells are presumably diluted inside a majority of cells governed by
alternative epigenetic patterns. Furthermore, we should consider
that neurons show a high variation in DNA methylation profiles
according to their unique characteristics (Iwamoto et al., 2011).
An additional complication arises from the interindividual variation
observed in humans which also contributes to mask such differ-
ences. These make the discovery of epigenetic alterations in
neurological diseases difficult and, as consequence, few genes
have, to date, been reported in widespread non-tumoral disorders
such as Alzheimer’s disease (Siegmund et al., 2009; Wang et al.,
2008; Bakulski et al., 2012; Rao et al, 2012).
To face this challenge, we focused on genetically homogeneous
mouse models because they show a reduced interindividual vari-
ation. In spite of the importance of mice models in scientific re-
search, no platforms interrogating mouse DNA methylation have
been commercialized and the available alternatives are not sensi-
tive enough to quantify the expected DNA methylation differences
in CNS (a comparison of methods is available in Harris et al.,
2010). For that, we designed a custom Illumina VeraCode DNA
methylation mouse array enriched in genes related to sensory per-
ception, cognition, neuroplasticity, brain physiology and mental
diseases. Illumina platforms have been demonstrated to be
Figure 3 Epigenetic deregulation of target genes in the frontal cortex of patients with Alzheimer’s disease. The gain of promoter
hypermethylation for the TBXA2R, SORBS3 and SPTBN4 genes in the Alzheimer’s disease frontal cortex determined by pyrosequencing
(A) (pyrosequencing values presented correspond to the average CpG methylation across each amplicon) is associated with the down-
regulation of the corresponding RNA transcripts (B) and proteins, measured by overall immunofluorescence (C). The same trend is
observed for F2RL2, but was not statistically significant. *P5 0.05 in the Student’s t-test.
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accurate genome-wide assays, commonly used to study DNA
methylation (Bock et al., 2010), and, as consequence, our
custom array could be a useful tool to identify DNA methylation
differences in mouse brain. However, there is the limitation that
only the DNA sequences included in the microarray can be studied
and the enrichment of candidate genes selected for their putative
role on neurological pathways creates a bias for these types of
candidates. Additionally, we have confined our study to the se-
quences 750 bp upstream and 250 bp downstream of the corres-
ponding transcription start sites and CpGs located in other
intragenic or intergenic DNA methylation regions, which could
also have an impact on gene activity. Importantly, there are
new challenges in the study of DNA methylation in the brain
and its disorders that should be considered, such as the presence
of hydroxymethylation (Kriaucionis and Heintz, 2009; Mu¨nzel
et al., 2010; Song et al., 2011; Szulwach et al., 2011; Khare
et al., 2012) which, unfortunately, cannot be distinguished by
standard bisulphite conversion (Huang et al., 2010) or the recog-
nition that DNA methylation is a dynamic process in brain regions,
including those associated with cognition and behaviour (Lubin
et al., 2011; Numata et al., 2012). In our study, we accomplished
a detailed description of DNA methylation profiles of 12 well-
defined mouse brain regions and used this information to highlight
the specific characteristics of affected regions in Alzheimer’s dis-
ease. Thus, we identified a subset of possible target genes for
Alzheimer’s disease that were interrogated in two different
Alzheimer’s mouse models and human samples achieving a high
correlation between the groups.
The DNA hypermethylation-associated inactivation of the
TBXA2R, F2RL2, SORBS3 and SPTBN4 genes discovered here in
samples of Alzheimer’s disease could provide additional clues to
understand the pathology of the disease. TBXA2R is a member of
the family of G protein-coupled receptors that regulates the cAMP
response element-binding protein (CREB) (Muja et al., 2001;
Obara et al., 2005). In this regard, the CREB activation pathway
is critical for neuron activity (Franklin et al., 1992). It has been
recently observed that other CREB-related genes are differentially
methylated across different cortex regions and cerebellum (Davies
et al., 2012) and CREB-signalling alterations occur in Alzheimer’s
disease (Saura and Valero, 2011). TBXA2R plays another import-
ant role in the pathobiology of Alzheimer’s disease by mediating
NMDA excitotoxicity (Mitsumori et al., 2011). NMDA treatment
induces apoptosis and the production of thromboxane A2 (TXA2)
(Okada et al., 2008). The ligand of TBXA2R establishes a link
between NMDA excitotoxicity and TXA2 signalling. Interestingly,
amyloid-b treatments also induce TXA2 production and are asso-
ciated with neurodegeneration, which is, in turn, attenuated by
TXA2 antagonists (Yagami et al., 2004). It is also important to
mention that F2RL2, identified in the Alzheimer’s mice models
but not completely validated in the human samples, is also asso-
ciated with NMDA excitotoxicity and is necessary for the APC-
mediated protection after NMDA treatments (Guo et al., 2004).
The second identified target of epigenetic inactivation, SORBS3, is
a gene previously reported to be hypermethylated in Alzheimer’s
disease (Siegmund et al., 2009). SORBS3, also known as vinexin,
is involved in synapsis (Ito et al., 2007) and regulates gene
expression (Matsuyama et al., 2005) and further research is ne-
cessary to understand its putative role in Alzheimer’s disease.
Finally, the third candidate, SPTBN4, is a prominent member of
the axon initial segment and, in combination with the ankyrin G
protein, acts as a bridge between the cytoskeleton and voltage-
gated channels (Grubb et al., 2010). The correct formation of the
axon initial segment is essential for synaptic integration and the
firing of the action potential (Palmer and Stuart, 2006; Kress et al.,
2010) and its disruption compromises neuronal function, organiza-
tion and polarity (Hedstrom et al., 2008). Indeed, Spnb4 mutant
mice fail to initiate action potentials and show progressive behav-
ioural deficits with altered network excitability (Uemoto et al.,
2007; Yang et al., 2007; Winkels et al., 2009). Most importantly
for Alzheimer’s disease, the integrity of the axon initial segment is
necessary to maintain the axonal localization of tau (Li et al.,
2011) and its disruption could result in tau mislocalization, increase
of tau presence in the somatodendritic compartment and
enhanced exposure to kinases. In this regard, SPTBN4 also anchors
CAMKII to the axon initial segment (Hund et al., 2010), and, thus,
CAMKII mislocalization upon SPTBN4 epigenetic loss could cause
tau hyperphosphorylation, a common finding in Alzheimer’s dis-
ease (Xiao et al., 1996). Supporting this hypothesis, RNA interfer-
ence of the SPTBN4 orthologue in a Drosophila Alzheimer’s
disease model also enhances tau toxicity (Shulman et al., 2011).
In addition, the mutant mice for ankyrin G (the partner of Spnb4
in axon initial segment) shows neurodegeneration (Zhou et al.,
1998), reinforcing the importance of axon initial segment integrity
in neuronal viability. Interestingly, the DNA-methylation associated
loss of SPTBN4 identified here could also contribute to Alzheimer’s
disease by another pathway: the alteration of amyloid precursor
protein processing. Alpha and beta-secretases, which are respon-
sible for non-amyloidic and amyloidic processing of amyloid pre-
cursor protein, tend to localize in the somatodendritic
compartment and plasmatic membrane, respectively (reviewed in
Haass et al., 2012). In this context, the non-amyloidic processing
of amyloid precursor protein occurs predominantly on the cell sur-
face and could depend on the integrity of the axon initial segment
that could be disrupted by SPTBN4 epigenetic silencing. Thus, the
observed DNA methylation-associated inactivation of SPTBN4
could relate to both tau hyperphosphorylation and an increase in
the amyloidic processing of amyloid precursor protein, the two
main hallmarks of Alzheimer’s disease.
Overall, our data suggest that key genes are altered by DNA
methylation in Alzheimer’s disease, highlighting the disruption of
particular molecular signalling pathways and cellular structures,
such as CREB-activation and the axon initial segment.
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